News Releases

February 2021

February 24, 2021 2/24/2021 Takeda Provides Updates on Phase 1/2 Clinical Trials of Novavax’ and Moderna’s COVID-19 Vaccine Candidates in Japan

February 12, 2021 2/12/2021 Takedas Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory With or Without Resistance Cytomegalovirus Infection Disease

February 10, 2021 2/10/2021 Takeda Submits New Drug Application to Manufacture and Market Darvadstrocel In Japan for Treatment of Complex Perianal Fistulas in Adult Patients with Crohn’s Disease

February 4, 2021 2/4/2021 Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

February 4, 2021 2/4/2021 Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS

February 3, 2021 2/3/2021 Data at EAHAD 2021 Highlight Value of Takeda’s Leading Hematology Portfolio in Clinical Settings and Commitment to Patient-Focused Advancements

February 1, 2021 2/1/2021 Takeda Completes Sale of TachoSil® to Corza Health

January 2021

January 29, 2021 1/29/2021 Takeda Completes Sale of Select OTC and Non-Core Assets to Hypera Pharma

January 28, 2021 1/28/2021 Takeda Presents Positive Results for Mobocertinib in Patients with EGFR Exon20 Insertion+ mNSCLC who Received Prior Platinum-Based Chemotherapy